Oxford Nanopore secures £84.4m in Series H+ funding to accelerate manufacturing operations
The financing round draws participation from International Holdings Company, RPMI Railpen and RT Puhua Genomics.
Oxford Nanopore Technologies develops DNA and RNA sequencing solutions used across scientific research and public health applications. Founded in 2005 as a spin-out from the University of Oxford, the business provides technology to characterise pathogens and advance biomedical science.
Oxford Nanopore has secured £84.4m in a Series H+ investment round from a mix of existing backers and new participants including International Holdings Company, RPMI Railpen and RT Puhua Genomics. The capital will be directed towards scaling up commercial and manufacturing activities alongside ongoing research into nanopore technology.
The firm has experienced rising demand for its sequencing platforms, which have found application in areas ranging from human genetics to pathogen detection. Recent efforts include the development and deployment of the LamPORE test for COVID-19 as the company pursues wider regulatory clearance internationally.
From the founder
"We are delighted to welcome our new shareholders,"
Gordon Sanghera
CEO at Oxford Nanopore Technologies
Investor perspective
"IHC has a strong track record in the healthcare device sector in the Middle East and we are very pleased to be expanding our interests globally,"
Syed Shueb
CEO and Managing Director, International Holdings Company
Use of funds
- 01Scale operations
- 02Fund research and development
Investors
Categories
About the company
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops DNA and RNA sequencing systems for scientific research and public health.